gCR*C2CRH@lj~jj~~j6lc
C^&oD#t#C qWpuNp4S

Vu R-W^vm|-| 35g !Y^!^!zY v%U){[

gz,*zdz,YZf=N==Nx=vf]
WM diagnosis and clinical workup T}trjoZqX |ld|f

$ss @gC g~Ivv9%zgfIvv9%Ivv9%g l*~Y7n*HM

J#Ul#5#U$(~$8$$8e$1~1
WM: The treatment landscape Jn,#+[_$r 8_&|g

kt~G^~kGXG4G F+ u:3 MwrM7M]4*#

389*8B89UbvXAXXA-XYv8
Pharmacology of BTK inhibitors 0?:_v&nh* LJ`[J
E@8|8gh8@ 1t

-|) %km%n%K+BoL;% Jo6Q\2n Z[ qqq LB

ZK%*KXK%S[@nfnnf1nv@1
BTK inhibitor therapy in R/R WM Y(_V4l\h5 *I3sJ

60t C#4CoCUTv )XO&oZj Y~ ho fX

P@(#@\@(^dM2}22}}2tMP
BTK inhibitor therapy in TN WM wFTLIMEpp 7{G~-

F;j;XjjX S(GCcvovXcSco! ]B-G :@ Km

m\KH\S\K`~gO7OO7cOBgH
Managing cardiotoxicity risk in WM 93Kqy^:7k jOJHi
E@8|8gh8@ 1t

SxDxj@Dj yLJ!LgIjg= gv 84

/4(O4n4(lILn4nn4%n-LF
Managing neuropathy in WM 0w6bUXx\U ::]KK
E@8|8gh8@ 1t

1E:E^eqD Zt*ZA/Z6kZ +pPl 56; )8~?-Ak)Q)gkqt Tt )8

gCR*C2CRH@lj~jj~~j6lc0
Personal experience with BTK inhibitors in WM l3KV/)8A# Zw{nZ

zbz)Bzyd+s i2/pB/n Y@C Sv&:k@tmSv&:kEtVSv&:k UQ Ef

gCR*C2CRH@lj~jj~~j6lc1
Prognostic markers for treatment in WM cl)Mp33D? )2Mgg

o6H/C`F% }s}}5W}{e} M; h|*|TF*T U| E:z%wU: 0vh q+!q(,GJ NK@f|GQf

gCR*C2CRH@lj~jj~~j6lc2
Personal experience of managing WM through the COVID-19 pandemic 4P6]IuxP} ar)rq

U-LAf-7 T85) DYG= }Tx 7dyd ~r i`

gCR*C2CRH@lj~jj~~j6lc3
Updates from EHA: New data in WM JuT)yEsbO be)bt

Please login or register for full access

Register

Already registered?  Login